TTNP — Titan Pharmaceuticals Income Statement
0.000.00%
Last trade - 00:00
- $6.48m
- $0.22m
- $0.18m
R2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 2.6 | 4.84 | 1.53 | 0.557 | 0.184 |
Cost of Revenue | |||||
Gross Profit | 2.6 | 4.37 | 1.33 | 0.557 | — |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 10.3 | 12.3 | 10.2 | 10.8 | 7.46 |
Operating Profit | -7.65 | -7.43 | -8.69 | -10.2 | -7.28 |
Total Net Non Operating Interest Income / Expense | |||||
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -7.49 | -7.41 | -8.78 | -10.2 | -5.57 |
Net Income After Taxes | -7.49 | -7.41 | -8.78 | -10.2 | -5.57 |
Net Income Before Extraordinary Items | |||||
Extraordinary Items | |||||
Net Income | -16.5 | -18.2 | -8.78 | -10.2 | -5.57 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -16.5 | -18.2 | -8.78 | -10.2 | -5.57 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -201 | -38.3 | -19.4 | -15.2 | -9.74 |